PedAM
Pediatric Disease Annotations & Medicines
| Disease | prostate cancer |
| Phenotype | C0242350|erectile dysfunction |
| Sentences | 9 |
| PubMedID- 22749428 | The stamp test should strongly be considered as an objective measure of erectile function in future studies of erectile dysfunction in patients with prostate cancer. |
| PubMedID- 20800031 | [erectile dysfunction in patients with prostate cancer who have undergone surgery: systematic review of literature]. |
| PubMedID- 22194777 | However, the most frequent aes following transrectal hifu were urinary incontinence (6–27%) and erectile dysfunction (50–77%) in patients with prostate cancer and hematospermia (20%) in benign hyperplasia, these rates were not reported for usgfu treatment [13], [14]. |
| PubMedID- 23678302 | Radical prostatectomy and radiation therapy as treatment options for localized prostate cancer are associated with erectile dysfunction. |
| PubMedID- 22330103 | Purpose: radiation therapy (rt) for prostate cancer is commonly associated with erectile dysfunction (ed), although high-quality data on incidence of ed after brachytherapy (bt) are limited. |
| PubMedID- 24809413 | Purpose of review: although no standard management of erectile dysfunction in prostate cancer (cap) survivors exists, many treatment options are available. |
| PubMedID- 23017516 | A prospective longitudinal survey of erectile dysfunction in patients with localized prostate cancer treated with permanent prostate brachytherapy. |
| PubMedID- 22548750 | Introduction: radiation therapy (rt) for prostate cancer is frequently associated with posttreatment erectile dysfunction (ed). |
| PubMedID- 22010127 | Phosphodiesterase type 5 inhibitors such as sildenafil (viagra) are widely and successfully used for post-surgical erectile dysfunction in patients with prostate cancer,1314 although it is known that unsuccessful treatment with phosphodiesterase type 5 inhibitors may reduce quality of life still further.15 however, the physical and psychological causes of erectile dysfunction in men with colorectal cancer and prostate cancer may not be the same.16 evidence on the use and effects of phosphodiesterase type 5 inhibitors after pelvic surgery for colorectal cancer is limited17 and it has not become part of routine planning after surgical treatment. |
Page: 1